Couple things to keep in mind: 1) The market for
Post# of 148168
1) The market for this indication was not especially lucrative, especially in contrast with monotherapy, not to mention NASH or oncology.
2) This decision paves the way to extract many pounds of flesh, cooked or uncooked (Respert's ears perk up here), in litigation vs. AmaWrecks.